Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Ziprasidone, Diabetes, Insulin Resistance
Eligibility Criteria
Inclusion Criteria: Diagnosis of Schizophrenia, any subtype or schizoaffective disorder Ages 18-65 years Capable of providing informed consent Antipsychotic Agents -associated diabetes mellitus, impaired fasting glucose or insulin resistance Stable dose of clozapine or olanzapine for at least 1 month Optimal dose of clozapine or olanzapine, or a maximal dose if limited by significant side effects Exclusion Criteria: Serious medical or neurological illness (unstable cardiac disease including recent myocardial infarction or heart failure, seizure disorder, malignancy, liver or renal impairment, etc.) Current substance abuse Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile History of serious blood dyscrasia requiring discontinuation of clozapine Serious suicidal or homicidal risk within the past six months History of diabetes mellitus prior to treatment with clozapine or olanzapine H/o prolongation of QTc interval (>450) on EKG or clinically significant EKG abnormalities. Treatment with medications that significantly prolong QTc interval such as dofetilde, sotalol, quinidine, class Ia and III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacine, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyul acetate, dolasetron myselate, probucol, or tacrolimus.
Sites / Locations
- Freedom Trail Clinic